ImmunityBio, Inc. IBRX Other revenues — Total Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about ImmunityBio, Inc.'s other revenues — total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ImmunityBio, Inc.'s other revenues — total revenue?
- ImmunityBio, Inc. (IBRX) reported other revenues — total revenue of $39K in Q1 2026.
- How has ImmunityBio, Inc.'s other revenues — total revenue changed year-over-year?
- ImmunityBio, Inc.'s other revenues — total revenue increased by 387.5% year-over-year, from $8K to $39K.
- What is the long-term trend for ImmunityBio, Inc.'s other revenues — total revenue?
- Over 3 years (2022 to 2025), ImmunityBio, Inc.'s other revenues — total revenue has grown at a 8.4% compound annual growth rate (CAGR), from $240K to $306K.
- What does other revenues — total revenue mean?
- This metric represents the aggregate revenue generated from business activities outside of the company's primary therapeutic product lines or core commercialized treatments. It typically encompasses ancillary income streams such as contract research services, licensing fees, or collaborative development arrangements that do not constitute the main revenue-generating focus. Tracking this figure helps investors understand the contribution of secondary business segments to the company's overall financial performance.